Ring Containing Patents (Class 514/559)
-
Publication number: 20140200274Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.Type: ApplicationFiled: April 6, 2012Publication date: July 17, 2014Applicant: Nexmed Holdings, IncInventors: Daniel W. Frank, Richard Martin, Bassam B. Damaj
-
Publication number: 20140179630Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.Type: ApplicationFiled: October 28, 2013Publication date: June 26, 2014Applicant: The Brigham and Women's Hospital, Inc.Inventors: Charles N. SERHAN, Bruce D. LEVY
-
Publication number: 20140170201Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.Type: ApplicationFiled: September 30, 2013Publication date: June 19, 2014Applicants: Drexel University, The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ilia Fishbein, Ivan Alferiev, Gennady Friedman, Darryl Williams
-
Publication number: 20140163102Abstract: The present invention provides a medical dressing for respiratory epithelial cells comprising a biocompatible polymer and retinoic acid, wherein, based on total volume of the dressing, the polymer is 99% or more, and retinoic acid is 1% or less.Type: ApplicationFiled: December 6, 2013Publication date: June 12, 2014Applicant: National Taiwan UniversityInventors: TAI-HORNG YOUNG, TSUNG-WEI HUANG, HSU-HSIEN CHANG
-
Patent number: 8735378Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.Type: GrantFiled: March 22, 2012Date of Patent: May 27, 2014Assignee: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
-
Patent number: 8735379Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.Type: GrantFiled: March 22, 2012Date of Patent: May 27, 2014Assignee: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
-
Patent number: 8729123Abstract: The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt % docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.Type: GrantFiled: October 3, 2011Date of Patent: May 20, 2014Assignee: N.V. NutriciaInventors: Bernd Stahl, Gunther Boehm, Christopher Beermann, Johan Garssen
-
Patent number: 8729293Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.Type: GrantFiled: March 22, 2012Date of Patent: May 20, 2014Assignee: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
-
Patent number: 8722737Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.Type: GrantFiled: April 30, 2012Date of Patent: May 13, 2014Assignee: SCF Pharma Inc.Inventor: Samuel Fortin
-
Patent number: 8722739Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.Type: GrantFiled: October 29, 2008Date of Patent: May 13, 2014Assignee: Novaer Holdings, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant
-
Publication number: 20140128398Abstract: Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.Type: ApplicationFiled: June 1, 2012Publication date: May 8, 2014Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Mark R. Kelley, Michael R. Vasko
-
Publication number: 20140121275Abstract: Feeding a diet supplemented with DDGS or another supplement containing UFA at a level above a threshold to animals such as swine, cattle, and poultry can have negative effects on carcass fat, certain growth parameters, and meat characteristics. However, if this diet is provided with a second supplement that contains CPFA at specified levels in the diet, the negative effects otherwise expected are wholly or at least partially countered. The invention recommends employing a supplemental source of CPFA between about 0.001% and about 0.5% of the diet by weight. Negative effects on carcass characteristics caused by ractopamine can also be countered by the addition of this amount of at least one source of CPFA in the diet.Type: ApplicationFiled: March 14, 2013Publication date: May 1, 2014Applicant: Value-Added Science & Technology, LLC.Inventors: Chad D. Hagen, Steven P. Weiss, Wayne Cast, Kenneth W. Purser, Ran Song, Dale Green
-
Patent number: 8710252Abstract: The present invention relates to enantiomeric forms of hepoxilin analogs of Formula I-VIII, pharmaceutical compositions thereof, a method for the separation of said enantiomeric forms of hepoxilin analogs comprising applying said hepoxilin to a chiral phase HPLC column and eluting said hepoxilin with an alkane and alcohol solvent mixture. Said enantiomeric forms of hepoxilin analogs of Formula I-VIII were found to be useful in controlling the biological effects of PPAR mediated transcriptional control for the treatment of diseases such as cancer, thromboxane-mediated diseases and for modulating intracellular calcium concentration.Type: GrantFiled: April 19, 2007Date of Patent: April 29, 2014Inventors: Cecil Pace-Asciak, Alexandra SantAna Sorensen, Jean-Philippe Meyer, Peter Denim
-
Publication number: 20140107203Abstract: The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DEBOECK, Francis VANDERBIST, Cecile SERVAIS, Philippe BAUDIER
-
Publication number: 20140094519Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.Type: ApplicationFiled: May 12, 2011Publication date: April 3, 2014Inventors: Charles N. Serhan, Reza Dana, Yiping Jin
-
Publication number: 20140086909Abstract: The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.Type: ApplicationFiled: March 14, 2012Publication date: March 27, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Kun Ping Lu, Shuo Wei, Xian Zhen Zhou
-
Publication number: 20140080775Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicants: UNIVERSITY OF WASHINGTON, The General Hospital Corporation, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20140066506Abstract: Disclosed is a method for treating macular degeneration in a mammalian subject, which includes administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2? isopropyl ester.Type: ApplicationFiled: November 5, 2013Publication date: March 6, 2014Applicant: SUCAMPO AGInventors: Ryuji UENO, John CUPPOLETTI
-
Publication number: 20140057982Abstract: The present invention provides new retinoid compounds and uses of the compounds in humans and animals for non-neoplastic dermal or inflammatory conditions or disorders.Type: ApplicationFiled: July 1, 2013Publication date: February 27, 2014Applicant: THE UAB RESEARCH FOUNDATIONInventors: Wayne J. Brouillette, Donald D. Muccio, Venkatram Reddy Atigadda, John M. Ruppert, Susan M. Ruppert
-
Publication number: 20140050676Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of a combination of retinoid boosters.Type: ApplicationFiled: February 11, 2013Publication date: February 20, 2014Applicant: Conopco, Inc., d/b/a UNILEVERInventor: Conopco, Inc., d/b/a UNILEVER
-
Patent number: 8637085Abstract: An aqueous disinfecting solution having a pH from about 0.5 to about 6 and consisting essentially of hydrogen peroxide in a concentration from about 0.05 to about 8 w/w % of the total solution; at least one anionic surfactant in a concentration from about 0.02 to about 8 w/w % of the total solution, selected from sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof; naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; and alkyl or alkenyl esters or diesters of sulfosuccinic acids in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof; and benzyl alcohol in a concentration from about 0.1 to about 10 w/w % of the solution.Type: GrantFiled: March 21, 2012Date of Patent: January 28, 2014Assignee: Virox Technologies Inc.Inventors: Jose A. Ramirez, Navid Omidbakhsh
-
Patent number: 8637571Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.Type: GrantFiled: March 23, 2010Date of Patent: January 28, 2014Assignee: Allergan, Inc.Inventors: Patrick M. Hughes, Orest Olejnik, Joan-En Chang-Lin
-
Patent number: 8623918Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.Type: GrantFiled: October 29, 2008Date of Patent: January 7, 2014Assignee: Novaer Holdings, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant
-
Patent number: 8623335Abstract: The present invention relates generally to composition and methods for topical application to skin. More particularly, it relates to treatment of scars and rosacea, and other aspects of skin care. A composition is disclosed having a skin toner for cleansing a skin surface, removing dead skin cells, restoring alkali balance, and shrinking skin pores; and a skin moisturizer for increasing water content in the external layers of the skin.Type: GrantFiled: September 9, 2008Date of Patent: January 7, 2014Inventor: Tauna Ann Waddington
-
Patent number: 8618168Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.Type: GrantFiled: May 21, 2010Date of Patent: December 31, 2013Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Hirosato Fujii, Motoo Yamagata
-
Publication number: 20130337077Abstract: Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from about 100 nm to about 300 nm. In further preferred embodiments, the nanosphere has a diameter of from about 150 nm to about 250 nm. In yet further embodiments, the nanosphere has a diameter of from about 180 nm to about 220 nm. In some embodiments, the oil comprises a lipid or a phospholipid. In further embodiments, the lipid or the phospholipid has a melting point below 20° C. In some embodiments, the polymer is a natural, modified or synthetic polymer. In further embodiments, the polymer is biodegradable.Type: ApplicationFiled: June 14, 2013Publication date: December 19, 2013Inventors: Ho Lun Wong, Mayuri Narvekar, Hui Yi Xue
-
Patent number: 8609629Abstract: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states; and kits provided for co-administration of various vitamin and mineral compositions, and in a specific embodiment, said kits comprise one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states.Type: GrantFiled: January 23, 2012Date of Patent: December 17, 2013Assignee: Evertt Laboratories, Inc.Inventors: John A. Giordano, Charles J. Balzer
-
Patent number: 8604229Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond the oral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.Type: GrantFiled: January 9, 2012Date of Patent: December 10, 2013Assignees: University of Southern California, Trustees of Boston University, Brigham and Women's Hospital, Inc.Inventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
-
Publication number: 20130315962Abstract: A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells.Type: ApplicationFiled: July 6, 2011Publication date: November 28, 2013Applicant: Nanologica ABInventors: Alfonso E. Garcia-Bennett, Elena Nickolaevna Kozlova
-
Publication number: 20130317106Abstract: Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof.Type: ApplicationFiled: April 4, 2013Publication date: November 28, 2013Applicant: The UAB Research FoundationInventors: Wayne J. Brouillette, Donald D. Muccio, Venkatram Reddy Atigadda, John M. Ruppert, Susan M. Lobo Ruppert
-
Patent number: 8574609Abstract: Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable.Type: GrantFiled: May 2, 2011Date of Patent: November 5, 2013Inventor: John Alex Lopes
-
Patent number: 8563535Abstract: An aqueous gel composition of the present invention comprising about 0.1 to 0.3 wt % adapalene and about 2.5 to 5.0 wt % benzoyl peroxide, as active ingredients, wherein both the active ingredients are stabilized in hydrophilic gelling matrix of pH dependent gelling agent comprising crosslinked, acrylic acid-based polymer(s).Type: GrantFiled: March 23, 2012Date of Patent: October 22, 2013Inventors: Kamal Mehta, Lalatendu Panigrahi, Uday Kumar Nayak, Balakrishna Patro
-
Publication number: 20130273019Abstract: A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the patient to cause healing, accelerated healing or prevention of the wound, ulcer or inflammation. Additional active ingredients may include a promoter of mitochondrial function or an antioxidant.Type: ApplicationFiled: December 4, 2012Publication date: October 17, 2013Inventor: BioChemics, Inc.
-
Publication number: 20130267598Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production.Type: ApplicationFiled: February 22, 2013Publication date: October 10, 2013Inventors: Mehar Manku, David Coughlan, Bill Downes, John Climax
-
Patent number: 8541469Abstract: 9-cis retinoic acid and pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, 9-cis retinal and pharmaceutically acceptable acetals thereof, and 9-cis retinol and pharmaceutically acceptable hydrolyzable esters thereof as well as metabolites of 9-cis retinoic acid have been found to be efficacious in treating T-helper cell type 1 mediated immune diseases in well tolerated doses. Preferably, the active ingredient is formulated as a medicament for oral or topical administration.Type: GrantFiled: May 12, 2006Date of Patent: September 24, 2013Assignee: Glaxo Group LimitedInventors: Werner Bollag, Fritz Ott
-
Patent number: 8541614Abstract: The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate.Type: GrantFiled: April 3, 2009Date of Patent: September 24, 2013Assignee: Metabolex, Inc.Inventors: Diego Broggini, Hartmut Burghard Zinser
-
Patent number: 8541362Abstract: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: August 21, 2006Date of Patent: September 24, 2013Assignee: Emisphere Technologies, Inc.Inventors: Pingwah Tang, Steven Dinh, Jongbin Lee, Puchun Liu, Gabriela Mustata
-
Publication number: 20130225521Abstract: A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B2, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, calcium, magnesium, zinc, boron and chromium in one or more specified ratios. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.Type: ApplicationFiled: April 9, 2013Publication date: August 29, 2013Inventor: Ralph BROWN
-
Publication number: 20130225681Abstract: Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R?C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: PROMETIC BIOSCIENCES INC.Inventors: Boulos Zacharie, Christopher Penney, Shaun Abbott, Lyne Gagnon, Brigette Grouix, Pierre Laurin
-
Publication number: 20130225683Abstract: New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: PROMETIC BIOSCIENCES INC.Inventors: Lyne Gagnon, Brigette Grouix, Pierre Laurin
-
Publication number: 20130217770Abstract: A chloride channel opener, especially a prostaglandin compound, is used for the treatment of functional gastrointestinal disorders. The prostaglandin compound can be, for example, a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 compound or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1 compound. The functional gastrointestinal disorders can be, for example, irritable bowel syndrome and/or functional dyspepsia. The treatment can include, for example, systemic administration 1-4 times per day or continuous administration of the compound in an amount of 0.01-100 ?g per day.Type: ApplicationFiled: March 18, 2013Publication date: August 22, 2013Applicant: SUCAMPO AGInventor: SUCAMPO AG
-
Publication number: 20130217769Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.Type: ApplicationFiled: December 13, 2012Publication date: August 22, 2013Applicants: GALEPHAR M/FInventors: Francis Vanderbist, Cécile Servais, Phillippe Baudier
-
Patent number: 8512723Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including, in particular, an antimicrobial lipid component, such as a fatty acid ester, fatty ether, or alkoxide derivative thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).Type: GrantFiled: September 8, 2004Date of Patent: August 20, 2013Assignee: 3M Innovative Properties CompanyInventors: Matthew T. Scholz, Dianne L. Gibbs, John T. Capecchi, Jeffrey F. Andrews
-
Patent number: 8505730Abstract: Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.Type: GrantFiled: August 23, 2012Date of Patent: August 13, 2013Assignee: JR Chem, LLCInventors: Jose E. Ramirez, Joseph R. Faryniarz
-
Publication number: 20130202712Abstract: The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and/or biodegradable polymeric carrier, and to the use of biocompatible and/or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent.Type: ApplicationFiled: March 2, 2011Publication date: August 8, 2013Applicant: VINDICO NANOBIO TECHNOLOGY, INC.Inventors: Eric M. Ostertag, Paul C. Tumeh, P. Peter Ghoroghchian
-
Patent number: 8492438Abstract: Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.Type: GrantFiled: February 4, 2011Date of Patent: July 23, 2013Assignee: Asan Laboratories Company (Cayman), LimitedInventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
-
Publication number: 20130184348Abstract: This method, which screens drugs that activate the skin, is characterized by causing candidate drugs to act on vascular endothelial cells, and selecting drugs that enhance the expression of PDGF-BB by the cells as a skin activation agent.Type: ApplicationFiled: September 14, 2011Publication date: July 18, 2013Inventors: Tsutomu Soma, Haruyo Yamanishi, Yumiko Ishimatsu
-
Patent number: 8481597Abstract: The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.Type: GrantFiled: March 28, 2012Date of Patent: July 9, 2013Assignee: Metabolex, Inc.Inventors: Kenneth Luskey, Jian Luo
-
Publication number: 20130165453Abstract: The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.Type: ApplicationFiled: July 19, 2012Publication date: June 27, 2013Inventors: Miao-Kun Sun, Daniel L. Alkon
-
Patent number: 8470882Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.Type: GrantFiled: October 29, 2008Date of Patent: June 25, 2013Assignee: Novaer Holdings, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant